New Product Acquisition

In today's business environment it has become clear that companies do not expect to develop everything in-house. There is increasing activity in the licensing arena with companies, large and small, looking to acquire new products by either in-licensing or straight acquisition.

Whilst much of the focus in such deliberations is rightly on the clinical and safety of any potential new drug, the API and formulation development aspects are equally important. A project where the chemistry, manufacturing and control (CMC) aspects have not been properly reviewed as part of the due diligence can present major problems for the efficient development and progression of the project. This could ultimately result in costly delays to launch, or even rejection of the marketing application.

FinnBrit Consulting can advise on all CMC aspects of in-licensing or acquisitions of new drug products.

Find us on FaceBook


All information published throughout is intended for information only, and does not contain any warranties, implied or otherwise.

Copyright © 2007 FinnBrit Consulting and Lenk Design. All rights reserved.

Site Map